At RXcarrier online pharmacy you can buy online prescription medications, generic drugs and herbal remedies.
Our online drug store offers more then 500 prescription drugs with affordable prices and free delivery

07 Jan 2012 12:35 AM

KAI commences enollment in KAI-4169 second Phase 2 study for CKD-MBD


KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).

The single-arm, open-label, multicenter, dose-titration study is designed to evaluate the effect of three times weekly intravenous bolus administration of KAI-4169 over a 12-week treatment period as assessed by percent change in parathyroid hormone (PTH) from baseline at the end of treatment. Secondary endpoints include proportion of subjects with ≥ 30% reduction in PTH from baseline, the proportion of subjects with PTH ≤ 300 pg/mL and the mean change from baseline in serum calcium and phosphorus.

Steven James, President and CEO of KAI, commented, "We are proud of the momentum and continued progress of KAI-4169, our lead program. We recently reported results of the first Phase 2 study of KAI-4169 at the annual meeting of the American Society of Nephrology in a late breaker poster presentation. We believe KAI-4169 may lead to greatly improved care for patients, and we look forward to reporting continued positive results and progress of our program."

To check status of your order and claim your FREE bonus pills,  
Call Toll-free:

1–855–444–5599

(9:00 am – 5:00 pm ET)